Brought to you by 
Mersana brings in $35mm through Series B-1 round
04 Mar 2015
Executive Summary
Mersana Therapeutics Inc. (antibody-drug conjugates (ADCs) for cancer) raised $35mm through its Series B-1 round led by existing backer New Enterprise Associates. New investors Rock Springs Capital and former head of R&D from BMS Elliott Sigal, MD, PhD, also participated, along with returning investors Pfizer Venture Investments and Fidelity Biosciences. Proceeds will fund development of Mersana's Fleximer ADCs, with an IND filing expected for one of them later this year.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Nanotechnology, Chips, etc.
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mersana brings in $35mm through Series B-1 round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice